Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

NCT01353040 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Marburg Hemorrhagic Fever

Interventions

DRUG: AVI-6003
DRUG: Placebo

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]